Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
== Other epitope-tag combinations == The principle of tandem-affinity purification of multiprotein complexes is not limited to the combination of CBP and Protein A tags used in the original work by Rigaut et al. (1999). For example, the combination of FLAG- and HA-tags has been used since 2000 by the group of Nakatani to purify numerous protein complexes from mammalian cells. Many other tag combinations have been proposed since the TAP principle was published.
== Physiology == Although not yet completely understood, the dawn phenomenon is thought to be caused by an exaggeration of the normal physiologic hormonal processes that occur overnight. Overnight, the human body sees increased levels of several hormones, most notably growth hormone and catecholamines, that lead to increased rates of glucose production and release from the liver. These hormones also inhibit the effects of insulin, leading to an overall increase in circulating blood glucose. This effect is amplified in patients with islet β-cell dysfunction such as diabetics. Notably throughout this process glucagon levels remain unchanged and the increased levels of cortisol observed overnight do not appear to be involved. Observed hyperglycemia secondary to the dawn phenomenon is often defined as an increase in blood glucose of at least >1.1 mmol/L (20 mg/dL) between the lowest level at night and the highest level before breakfast; however, actual ranges may vary. The physiologic process involved in causing the dawn phenomenon has been shown to occur in most people. In non-diabetic patients, there is a modest increase in insulin secretion just before dawn which compensates for the increased glucose being released from the liver to prevent hyperglycemia. However, studies have shown that diabetic patients fail to compensate for this transiently increased blood glucose release, resulting in hyperglycemia. This resulting hyperglycemia is clinically relevant in diabetic patients as its lasting effects can lead to overall poor glycemic control.
-based regularization in a wavelet or other domain), such as via Ulf Grenander's Sieve estimator or via Bayes penalty methods or via I.J. Good's roughness method may yield superior performance to expectation-maximization-based methods which involve a Poisson likelihood function but do not involve such a prior. Attenuation correction: Attenuation occurs when photons emitted by the radiotracer inside the body are absorbed by intervening tissue between the detector and the emission of the photon. As different LORs must traverse different thicknesses of tissue, the photons are attenuated differentially. The result is that structures deep in the body are reconstructed as having falsely low tracer uptake. This must be corrected for when using quantitative PET imaging. One option for estimating attenuation coefficients is via a transmission scan, using a 68Ge rod source that is rotated around the patient Transmission scans directly measure attenuation values at 511 keV. With PET-CT scanners the 511 keV photon attenuation coefficients can be estimated using the Hounsfield units from the CT scan. Attenuation correction in PET-MRI scanners is more challenging, as the MRI images do not directly contain information on about the tissue attenuation coefficients, and the scanner bores are too narrow for a transmission scan.
=== Machine guns === Vickers machine gun – Not declared obsolete until 1968. Bren light machine gun – Original .303 versions used in early stages of the Cold War, L4A1-A6 7.62mm NATO variants in service from 1955 onwards. M1919 Browning machine gun - Mounted on vehicles and ground tripods L7A1/A2 GPMG - Adopted in 1958. Primary infantry machine gun until the 1980s, when it was replaced in infantry sections by the L86A1 listed below (though it remained in use with support company machine gun platoons). Also mounted on various vehicles. L86A1 Light Support Weapon - Initial batches issued in 1985; frontline Army units, Royal Marines, and RAF Regiment scheduled to be fully equipped by 1987, rest of regular Army scheduled to be fully equipped by 1990.
Sources: en.wikipedia.org
Neptunium (93Np) is usually considered an artificial element, although trace quantities are found in nature, so a standard atomic weight cannot be given. Like all trace or artificial elements, it has no stable isotopes. The first isotope to be synthesized and identified was 239Np in 1940, produced by bombarding 238U with neutrons to produce 239U, which then underwent beta decay to 239Np. Trace quantities are found in nature from neutron capture reactions by uranium atoms, a fact not discovered until 1951. Twenty-five neptunium radioisotopes have been characterized, with the most stable being 237Np with a half-life of 2.144 million years, 236Np with a half-life of 153,000 years, and 235Np with a half-life of 396.1 days. All of the remaining radioactive isotopes have half-lives that are less than 4.5 days, and the majority of these have half-lives that are less than 50 minutes. This element also has five meta states, with the most stable being 236mNp (t1/2 22.5 hours). The isotopes of neptunium range from 219Np to 244Np, though the intermediate isotope 221Np has not yet been observed. The primary decay mode for nuclei lighter than the most stable isotope, 237Np, is electron capture (and also alpha emission), and the primary mode after is beta emission. The primary decay products for nuclei lighter than 237Np are isotopes of uranium and protactinium, and the primary products after are isotopes of plutonium. Neptunium is the heaviest element for which the location of the proton drip line is known; the lightest proton-bound isotope is 220Np.
Barnes (December 2002). "Road Work: Racial Profiling and Drug Interdiction on the Highway". Michigan Law Review (Submitted manuscript). 101 (3): 653–751. doi:10.2307/1290469. JSTOR 1290469. Beckett, Katherine; Nyrop, Kris; Pfingst, Lori; Bowen, Melissa (August 2005). "Drug Use, Drug Possession Arrests, and the Question of Race: Lessons from Seattle". Social Problems. 52 (3): 419–441. doi:10.1525/sp.2005.52.3.419. Banks, R. Richard (December 2003). "Beyond Profiling: Race, Policing, and the Drug War". Stanford Law Review. 56 (3): 571. Stephanie R. Bush-Baskette (2004). "12. "The War on Drugs as a War on Black Women"". In Meda Chesney-Lind; Lisa Pasko (eds.). Girls, women, and crime: selected readings. SAGE. ISBN 978-0-7619-2828-7. Ruiz, Jim; Woessner, Matthew (Autumn 2006). "Profiling, Cajun style: racial and demographic profiling in Louisiana's war on drugs". International Journal of Police Science & Management. 8 (3): 176–197. doi:10.1350/ijps.2006.8.3.176. S2CID 145127716. Illya Lichtenberg (March 2006). "Driving While Black (DWB): Examining Race as a Tool in the War on Drugs". Police Practice & Research. 7 (1): 49–60. doi:10.1080/15614260600579649. S2CID 143784397. Katherine Beckett; Kris Nyrop; Lori Pfingst (February 2006). "Race, Drugs, and Policing: Understanding Disparities in Drug Delivery Arrests". Criminology. 44 (1): 105–137. doi:10.1111/j.1745-9125.2006.00044.x. Bobo, Lawrence D.; Victor Thompson (Summer 2006). "Unfair By Design: The War on Drugs, Race, and the Legitimacy of the Criminal Justice System" (PDF). Social Research. 73 (2): 445–472.
In 2024, Albirex Niigata Singapore underwent localisation with players now predominantly Singaporean. This as well as the exit of DPMM FC means that from the 2025–26 season, all participants of the Singapore Premier League are local clubs. In recent years, foreign clubs from other countries have also been invited to participate in the Singapore Cup. The most recent entrant was BG Pathum United of the Thai League 1 at the 2024–25 Singapore Cup.
This theoretical analysis of the various isomers and experimental analysis of this reaction cast doubt on whether the mass spectrometric approach really did produce the hexathione isomer as originally claimed. The increased stability of dithietes as compared to dioxetane-like rings is one of theoretical bases for proposing C6S6 is more stable than the oxygen analog.
Inhibition of radical SAM enzyme MqnE in menaquinone biosynthesis is reported to be an effective antibacterial strategy against H. pylori. Radical SAM enzyme BlsE has been discovered to be a central enzyme in blasticidin S biosynthetic pathway. Blasticidin S produced by Streptomyces griseochromogenes exhibits strong inhibitory activity against rice blast caused by Pyricularia oryzae Cavara. This compound specifically inhibits protein synthesis in both prokaryotes and eukaryotes through inhibition of peptide bond formation in the ribosome machinery. A new fungal radical SAM enzyme has also been reported to facilitate the biocatalytic routes for synthesis of 3'-deoxy nucleotides/nucleosides. 3'deoxynucleotides are a class of drugs that interfere with the metabolism of nucleotides, and their incorporation into DNA or RNA terminates cell division and replication. This activity explains why this compound is an essential group of antiviral, antibacterial or anticancer drug.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.